“YOU’LL PAY LESS” — TRUMP’S PROMISE JUST TOOK A MAJOR TURN, AND AMERICANS ARE ABOUT TO SEE WHY
For months, Donald Trump has made a simple promise to Americans: healthcare and prescription drugs should cost less.
Now that promise has entered a very different phase.
On September 18, the Trump administration announced that all 50 states, Washington, D.C., and Puerto Rico had joined a new Medicaid drug-pricing model built around so-called Most-Favored-Nation pricing.
That means the administration is no longer talking about lower drug prices only as a White House goal.
It is now extending the program across every state Medicaid system.
And that is where the real question begins:
Will Americans actually feel the difference in their wallets?
THE BIG CHANGE: ALL 50 STATES ARE IN
The announcement marked a major expansion of Trump's prescription-drug strategy.
Under the new GENEROUS Medicaid model, participating pharmaceutical companies will provide rebates on certain brand-name drugs so that the final price paid by Medicaid does not exceed the comparable Most-Favored-Nation price — essentially tying U.S. Medicaid prices to prices paid in other developed countries.
The program covers hundreds of drugs across major categories, including medicines for cancer, diabetes and asthma.
And the scale is important.
The administration says the program could generate about $64.3 billion in Medicaid savings over 10 years, with roughly $36.6 billion going to the federal government and $27.6 billion benefiting state governments.
For Trump, that is the latest piece of a broader affordability argument.
He has repeatedly said Americans have been paying far more for prescription drugs than people in other developed nations.
Now the administration is attempting to change that pricing structure.
TRUMP'S CLAIM IS BIGGER THAN MEDICAID
Here's where the story gets more interesting.
The new Medicaid program is only one part of the administration's broader drug-pricing campaign.
The White House says Trump has now secured agreements with 26 pharmaceutical manufacturers, covering about 89% of the branded drug market.
Those agreements are designed to bring U.S. prices closer to the lowest prices paid in comparable developed countries.
The administration also points to TrumpRx, its direct-to-consumer prescription drug platform.
According to the White House, TrumpRx has already generated more than $700 million in savings and offers discounts on hundreds of medicines.
The administration says some GLP-1 medications that previously cost more than $1,000 per month can now be obtained through the platform for as little as $149, while certain eligible Medicare seniors can pay $50 per month.
Those are administration figures, however, and the exact savings available to an individual patient depend on the specific medication, eligibility and purchasing arrangement.
That distinction matters.
Because “drug prices are coming down” and “every American will pay less” are not necessarily the same statement.
THE NUMBER TRUMP WANTS AMERICANS TO NOTICE
Trump has repeatedly emphasized the scale of the change.
During remarks on September 18, he said his administration had reached agreements with 26 major pharmaceutical companies and claimed that discounts on some drugs could reach 60%, 70%, 80% or even 90%.
He also said the new Medicaid model would cover nearly 70 million Americans.
But the administration's larger claim goes beyond individual discounts.
The White House says the lower prices could reduce government healthcare spending, freeing state and federal resources for other healthcare needs.
That is why the Medicaid expansion matters politically and financially.
If states spend less on prescription drugs, they potentially have more money available elsewhere in their Medicaid budgets.
The question is how much of that theoretical savings ultimately translates into improved services, lower costs or other benefits for patients.
THEN CAME THE SURPRISE: FREE MEDICATION
One of the most striking details in the announcement came from Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services.
Oz said Eliquis, a widely used blood-thinning medication, would have 1 million doses donated through Medicaid programs.
He described free medication as the next step beyond Most-Favored-Nation pricing.
That does not mean all prescription drugs will become free.
But it illustrates the administration's attempt to combine lower negotiated prices with direct drug donations.
And for Medicaid recipients who depend on expensive medications, that distinction could matter far more than the political argument surrounding the program.
BUT THERE IS A BIG CATCH
The headline sounds simple:
Americans pay less.
The actual system is much more complicated.
Most-Favored-Nation pricing applies to participating drugs and manufacturers. It does not mean every prescription in America suddenly receives the lowest international price.
The program is also focused heavily on Medicaid, while Trump's broader agreements and TrumpRx operate through different mechanisms.
And critics have questioned how much of the promised savings will ultimately materialize.
Reuters previously reported that some pharmaceutical companies and industry groups have raised concerns about the financial effects of the policy and questioned whether the administration has sufficient legal authority for parts of the program.
Other analysts have also questioned how much of the recent decline in prescription prices can be attributed directly to Trump's policies rather than other forces in the pharmaceutical market and earlier Medicare negotiations.
So the real test is not the announcement.
It is what happens when patients actually fill prescriptions.
WHY THIS COULD BECOME A MUCH BIGGER STORY
There is another reason this development matters.
Trump has been making affordability one of the central themes of his second-term economic message.
At the Republican midterm convention, he argued that prices were coming down even as affordability remained a major concern for Americans. CBS reported that the national average price of gasoline was still above $4 per gallon and inflation was running at 3.4% in September.
Prescription drugs are therefore only one piece of a much larger affordability debate.
If patients begin seeing significantly lower prices on widely used medicines, the administration will have a concrete example to point to.
If the savings are smaller, limited to certain drugs, or difficult for patients to access, the promise becomes much harder to measure in everyday life.
That is why the next stage may be more important than the announcement itself.
WHAT HAPPENS NEXT?
The administration now has to turn agreements and projected savings into something Americans can actually see.
For Medicaid, that means implementing the new pricing model across all 50 states, Washington, D.C. and Puerto Rico.
For consumers outside Medicaid, it means expanding access to the lower prices offered through agreements and TrumpRx.
And for Congress and policymakers, there is another unresolved question: how durable are these arrangements?
The administration has said it wants Congress to enact its broader Great Healthcare Plan, which it describes as a way to lower prescription drug prices, reduce insurance premiums and increase price transparency.
That would move the debate beyond executive agreements and toward legislation.
For now, the biggest change is already visible.
Trump's promise to lower drug prices has moved from a campaign-style talking point into a nationwide Medicaid pricing program involving every state.
But the final verdict will not come from the White House podium.
It will come from pharmacy counters, Medicaid budgets and patients looking at the number on their prescription bill.
May you like
Because the question Americans ultimately care about is much simpler than the policy language:
When they reach the pharmacy counter — will they actually pay less?
